Can a New Jersey resident get peptides by telehealth?
N.J.S.A. 45:1-61 through 45:1-66 (P.L.2017, c.117, as amended by P.L.2021, c.310, effective December 21, 2021) let a New Jersey-licensed health care provider establish a provider-patient relationship and treat through telemedicine, held to the in-person standard of care. As amended, N.J.S.A. 45:1-62(c) says telemedicine may be provided using interactive, real-time, two-way communication technologies or asynchronous store-and-forward technology. Store-and-forward may be used with or without real-time audio if, after reviewing the patient's medical records, the provider determines the in-person standard of care can be met and tells the patient so at the outset. Under N.J.S.A. 45:1-63, a proper relationship requires identifying the patient, disclosing the provider's credentials, reviewing the patient's history and records before an initial encounter, and determining before each encounter whether the in-person standard of care can be met by telemedicine. Unless that relationship exists, a provider may not prescribe based solely on responses to an online static questionnaire. The Board of Medical Examiners' rule N.J.A.C. 13:35-6B.5, adopted in 2020, still calls for real-time communication with video, but it predates the 2021 amendment, and this record treats the later statute as controlling. Schedule II prescribing by telemedicine generally requires an initial in-person exam, which does not apply to the non-controlled peptides in this database. This record classifies asynchronous prescribing as allowed because the amended statute expressly permits store-and-forward services without any real-time interaction. [2] [3] [4] [5] [9]
How does the New Jersey pharmacy board treat compounding?
| Board | New Jersey State Board of Pharmacy (Division of Consumer Affairs) |
|---|---|
| Eligible substances | Follows the federal 503A framework |
The Board of Pharmacy regulates pharmacy under the Pharmacy Practice Act of 2003 (N.J.S.A. 45:14-40 and following) and N.J.A.C. 13:39, including subchapter 11 on compounding sterile preparations. N.J.S.A. 45:14-73 requires any pharmacy located in another state that ships, mails, distributes, or delivers prescription legend drugs into New Jersey to register with the Board, submit its most recent home-state inspection report, and provide a toll-free line to a pharmacist with access to patient records; N.J.A.C. 13:39-4.20 implements the registration. Board rule N.J.A.C. 13:39-11.25 bars compounding a commercially available drug product unless the prescriber determines the change produces a significant difference for the patient. In its statement on semaglutide compounding (the version posted on the Board's site is dated November 6, 2023), the Board said that no salt form of semaglutide may be used in a compounded drug, and that a pharmacy using semaglutide base must ensure it is pharmaceutical grade, accompanied by a valid certificate of analysis, and sourced from an FDA-registered establishment. New Jersey has no state bulks list; peptide eligibility follows the federal 503A framework. [1] [6] [7] [8] [10] [12]
Can you get compounded GLP-1s in New Jersey?
Compounded semaglutide and tirzepatide are limited to the federal exception for documented patient specific needs because the FDA shortage allowances ended in 2025, and the Board's 2023 statement independently bars semaglutide salt forms and requires documented, FDA-registered sourcing of semaglutide base. [10] [15]
Prices by channel: semaglutide cost, tirzepatide cost.
Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.
What is the legal access path in New Jersey?
Access options
Prescriber licensed in New Jersey, in person or by telehealth
Telehealth prescribing of non-controlled peptides is permitted in New Jersey. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. State law says an online questionnaire alone is not enough.
Check the dispensing pharmacy against the board's license lookup before paying, including out-of-state mail-order pharmacies.
Branded GLP-1 through a retail or manufacturer pharmacy
FDA approved semaglutide and tirzepatide are available by prescription. Compounded GLP-1 limited; see the GLP-1 section for why.
CJC-1295 / Ipamorelin from Bodybuilding Peptides
SponsoredPartner lists from $220/month
Tesamorelin / Ipamorelin from Bodybuilding Peptides
SponsoredPartner lists from $274/month
Semax / Selank from Bodybuilding Peptides
SponsoredPartner lists from $274/month
We may earn a commission from these links.
Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.
Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.
Find a provider in New Jersey
What you'll actually find in New Jersey, and how to check
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [19] [20] [21]
No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [22]
What New Jersey has done
PeptideAgent has not found a board or legislative action on peptides in New Jersey.
Other states have acted:
- On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [24] Mississippi law
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [25] [26] Louisiana law
Checking the prescriber
Telehealth prescribing of non-controlled peptides is permitted in New Jersey. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. State law says an online questionnaire alone is not enough. [2] [3] [4] [5] [9] The telehealth rule in full.
Checking the pharmacy
Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the New Jersey State Board of Pharmacy (Division of Consumer Affairs); its license search: FDA BeSafeRx: state board of pharmacy license lookups. [23]
If you're going ahead anyway
These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [22]
They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [13] [27] [28]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [23] [29] [30]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [21] [30] [31]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [22] [32] [33] [34] [35] [36]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [22]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [23]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [21]
- Pharmacy: Is this made for me on a prescription written in my name? [31]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [21] [30]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [21]
What is offered for a specific peptide, and what FDA found, is on each peptide page.
Is it legal to buy research peptides in New Jersey?
New Jersey's food and drug law (N.J.S.A. Title 24) prohibits selling adulterated or misbranded drugs, and the Pharmacy Practice Act limits dispensing to licensed pharmacies. The Board's semaglutide statement also warns pharmacies against non-pharmaceutical-grade ingredients. [6] [10] [11] [16]
Peptide-specific notes for New Jersey
| Peptide | Note |
|---|---|
| Semaglutide | Available branded by prescription, including by telemedicine under N.J.S.A. 45:1-61 and following. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025, and the New Jersey Board of Pharmacy bars any salt form of semaglutide in compounding. [10] [15] |
| BPC-157 | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. On October 28, 2026 HHS released a draft enforcement discretion policy covering single-ingredient BPC-157 compounded by a state-licensed pharmacy by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's tested substance, with serious adverse events reported to FDA. It is not an FDA approval, is not binding, and does not cover blends such as Wolverine. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). New Jersey pharmacies apply the federal eligibility test and the Board's sourcing expectations for pharmaceutical-grade ingredients. [10] [13] [14] [17] [18] |
Frequently asked questions
Can I get a GLP-1 prescription in New Jersey through telemedicine?
Yes, from a New Jersey-licensed provider. The Telemedicine and Telehealth Act lets providers establish a relationship and prescribe through telemedicine under the in-person standard of care, and semaglutide and tirzepatide are not controlled substances. A provider may not prescribe based solely on an online static questionnaire unless a proper provider-patient relationship has been established under N.J.S.A. 45:1-63. [2] [3] [5]
Does New Jersey allow asynchronous or store-and-forward telemedicine?
Yes, with conditions. As amended in 2021, N.J.S.A. 45:1-62 says telemedicine may be provided using real-time, two-way communication or asynchronous store-and-forward technology. Store-and-forward may be used with or without real-time audio if the provider reviews the patient's medical records, determines the in-person standard of care can be met, and tells the patient so at the outset. A provider may not prescribe based solely on an online static questionnaire unless a proper provider-patient relationship has been established. The Board of Medical Examiners' 2020 rule still calls for real-time communication with video. It predates the 2021 amendment, and this record treats the later statute as controlling. [2] [3] [5] [9]
What did the New Jersey Board of Pharmacy say about compounded semaglutide?
In a 2023 statement (the version on the Board's site is dated November 6, 2023) the Board said that no salt form of semaglutide may be used in compounding, and that semaglutide base must be pharmaceutical grade, carry a valid certificate of analysis, and come from an FDA-registered establishment. [10]
Is compounded semaglutide or tirzepatide still available in New Jersey?
Only in limited, patient specific cases. The federal shortage allowances ended in 2025, and New Jersey also bars semaglutide salt forms, so routine compounded GLP-1 programs are not lawful. [10] [15]
Can a New Jersey pharmacy compound BPC-157?
Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: New Jersey has no state bulks list; peptide eligibility follows the federal 503A framework. [12] [13] [14] [17] [18]
From the blog
- Can you get a GLP-1 through telehealth in your state?
Yes in every state, but the rules for the visit, the prescriber's license, and the pharmacy differ. How state telehealth law shapes GLP-1 access, with state examples.
Sources
Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.
- [1]New Jersey State Board of Pharmacy (Division of Consumer Affairs)
- [2]N.J.S.A. 45:1-62, Provision of health care through use of telemedicine, telehealth; requirements for provider (Justia mirror, 2025 edition, as amended by P.L.2021, c.310; the official session law P.L.2021, c.310 is the primary source)
- [3]N.J.S.A. 45:1-63, Establishment of proper provider-patient relationship; exceptions (Justia mirror, 2025 edition)
- [4]New Jersey P.L.2017, c.117 (S291), Telemedicine and Telehealth Act
- [5]New Jersey P.L.2021, c.310 (S2559), amending the Telemedicine and Telehealth Act, approved December 21, 2021
- [6]New Jersey Pharmacy Practice Act, N.J.S.A. 45:14-40 and following, and N.J.A.C. 13:39 (Board laws and regulations)
- [7]N.J.S.A. 45:14-73, Registration of out-of-State pharmacies; requirements
- [8]N.J.A.C. 13:39-4.20, Out-of-State pharmacy registration
- [9]N.J.A.C. 13:35-6B.5, Provision of health care services through telemedicine or telehealth (Board of Medical Examiners)
- [10]New Jersey State Board of Pharmacy: Statement concerning semaglutide compounding (posted version dated November 6, 2023)
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). Are peptides legal in New Jersey?. https://peptideagent.ai/legal/new-jersey- HTML link
<a href="https://peptideagent.ai/legal/new-jersey">Are peptides legal in New Jersey?</a>, PeptideAgent, updated October 28, 2026.